TY - JOUR T1 - Proactive COVID-19 testing in a partially vaccinated population JF - medRxiv DO - 10.1101/2021.08.15.21262095 SP - 2021.08.15.21262095 AU - Ryan S. McGee AU - Julian R. Homburger AU - Hannah E. Williams AU - Carl T. Bergstrom AU - Alicia Y. Zhou Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/08/18/2021.08.15.21262095.abstract N2 - During the initial stages of the COVID-19 pandemic, many workplaces and universities implemented institution-wide proactive testing programs of all individuals, ir-respective of symptoms. These measures have proven effective in mitigating outbreaks. As a greater fraction of the population becomes vaccinated, we need to understand what continued benefit, if any, proactive testing can contribute. Here, we address this problem with two distinct modeling approaches: a simple analytical model and a more simulation using the SEIRS+ platform. Both models indicate that proactive testing remains useful until a threshold level of vaccination is reached. This threshold depends on the transmissibility of the virus and the scope of other control measures in place. If a community is able to reach the threshold level of vaccination, testing can cease. Otherwise, continued testing will be an important component of disease control. Because it is usually difficult or impossible to precisely estimate key parameters such as the basic reproduction number for a specific workplace or other setting, our results are more useful for understanding general trends than for making precise quantitative predictions.Competing Interest StatementCTB and RSM consult for Color Health. CTB has received honoraria from Novartis. HEW and AYZ are currently employed by and have equity interest in Color Health. JRH is currently employed and has an equity interest in Maze Therapeutics; he was previously employed by and holds an equity stake in Color Health.Funding StatementThis work was supported in part by the Rockefeller foundation's COVID-19 Modeling Accelerator. CTB and RSM were paid consultants for Color Health.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:N/AAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe code for and data from the SEIRS+ simulations used in this paper are available at https://github.com/ryansmcgee/covid-testing-vaccinated-population Mathematica code for the analytical model is included as supplementary material. The SEIRS+ codebase is open source and available at https://github.com/ryansmcgee/seirsplus. https://github.com/ryansmcgee/covid-testing-vaccinated-population ER -